Zhejiang Conba Pharmaceutical (600572.SH) subsidiary obtained drug registration certificate for Telmisartan Amlodipine Tablets ()
Conba (600572.SH) announced that recently, its wholly-owned subsidiary Hangzhou Conba Pharmaceutical Co., Ltd. (referred to as "Hangzhou Conba") has received the approved and issued Drug Registration Certificate for the Telmisartan Amlodipine Tablets () from the National Medical Products Administration.
Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary Hangzhou Zhejiang Conba Pharmaceutical Co., Ltd. (referred to as "Hangzhou Zhejiang Conba Pharmaceutical") has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the Telmisartan Amlodipine Tablets (II).
Telmisartan Amlodipine Tablets is a compound preparation composed of telmisartan and amlodipine. It was approved for listing in the United States in October 2009 and in China in September 2017. It is used to treat primary hypertension; or as an alternative therapy for patients receiving telmisartan and amlodipine tablets for combined treatment who can switch to receiving the same dose of this product. Currently, there are two formulations of Telmisartan Amlodipine Tablets available in the domestic market, one containing Telmisartan 80mg and Amlodipine besylate 5mg, and the other containing Telmisartan 40mg and Amlodipine besylate 5mg.
Related Articles
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
RECOMMEND
